Comera SPAC Presentation Deck
SQ Dosing Strongly Preferred Over IV by Physicians
Comera conducted market study
with over 50 physicians to assess
unmet need
Over 70% expressed interest in a SQ
version of an IV biologic if available
A clear majority agreed that patient
inconvenience was a significant issue
with IV
"Traveling and infusion time can sometimes take up
half a day for some of my patients. If there were an
option to take [the treatment] at home, many of them
would be very interested."
- Gastroenterologist in Midwest U.S.
Inconvenience to the patient
Top issues creating lack of physician
satisfaction with IV biologic dosage forms
Patient reluctance
Compliance to therapy
Injection site pain
I don't have enough staff to
administer treatment
I don't have enough staff to
schedule administration
Source: Ipsos market study and Comera physician interviews, December 2021; base: Total HCPs; n=50+ 5 IDIs with high-prescribing physicians.
11
30%
16%
52%
45%
(.<)
75%
Comera
LIFE SCIENCES
68%
13View entire presentation